[Acoustic rhinometry in the assessment of the topical treatment of upper respiratory infections with fusafungin].
The aim of the study was to estimate by means of acoustic rhinometry (AR) the nasal blockade in 37 patients (5-73 years old, mean 32) with upper airways infections treated by fusafungine. The examinations were carried out on the first (D1) and seventh day (D7) of observation. Cross-sectional area (CA) mean values of 3 cm sector laid back to C notch of AR curves (CA-C3) were selected to the analysis.


RESULTS
The mean value of CA-C3: in all patients it was 2.61 cm2 on D1 and 2.8 cm2 on D7; in rhinitis and sinusitis patients--2.23 cm2, in others--3.16 cm2; without nasal discharge--3.48 cm2, in others (with severe or medium)--2.53 cm2 and 2.48 cm2 respectively. 29 patients had nasal blockade (78.4%) with mean CA-C3 = 2.34 cm2 (others--3.56, p < 0.05). During seven days the following enlargement of CA-C3 was reported: 14.9% in all patients (p < 0.01); in viral infections 24% (n = 14, p < 0.01), bacterial 14.3% (n = 11, NI); in nasal blockade patients--15.22%, others--13.55% (p < 0.01). Mean value of CA-C3 increased by 37.7% in patients who demonstrated, according to the physicians, "very good improvement", 5.7%--"good", 1.5%--"weak" (p < 0.05). There was also enlargement of nasal cavities in CA-C3 in non-sneezers (p < 0.05) and medium discharge symptom patients (p < 0.05). There was no statistical difference in clinical and acoustic rhinometry results between patients treated with fusafungine together with non-steroid anti-inflammatory drugs and patients treated with fusafungine.


CONCLUSIONS
AR is a good instrument to be used in the objective assessment of the nasal blockade changes in people with infection of the nasal mucosa and showed positive efficacy of fusafungine in the treatment of upper airway infection.
Katedra i Klinika Otolaryngologii Akademii Medycznej w Warszawie.
B
B
Samoliński
A
A
Grzanka
E
E
Zawisza
M
M
Arcimowicz
D000162:Acoustics; D000293:Adolescent; D000328:Adult; D000336:Aerosols / Q000627:therapeutic use; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D047630:Depsipeptides; D005260:Female; D005670:Fusarium; D006801:Humans; D008297:Male; D008875:Middle Aged; D015508:Nasal Obstruction / Q000175:diagnosis* / Q000209:etiology; D010256:Paranasal Sinuses / Q000502:physiology*; D012141:Respiratory Tract Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012220:Rhinitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012852:Sinusitis / Q000175:diagnosis / Q000188:drug therapy
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin
Zastosowanie rynometrii akustycznej w ocenie skuteczności miejscowego leczenia fusafungina niezytów infekcyjnych górnych dróg oddechowych.